{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012194","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2022-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.620474+00:00","generated_at":"2026-06-24T22:56:42.036835+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kezar Phase 2 MISSION trial: 64.7% overall renal response rate in lupus nephritis","bullets":["11 of 17 patients (64.7%) achieved overall renal response (≥50% reduction in UPCR) at 6 months.","6 of 17 patients (35.2%) achieved complete renal response (UPCR ≤0.5, eGFR stable, steroids ≤10 mg/day).","Zetomipzomib well tolerated; most AEs mild-to-moderate; no Grade 3 infections reported.","Mean daily prednisone reduced from 19.2 mg at baseline to 9.1 mg at end of treatment.","Company plans continued development for lupus nephritis and evaluation for systemic lupus erythematosus."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012194","json":"https://secwatch.observer/filing/0000950170-22-012194.json","markdown":"https://secwatch.observer/filing/0000950170-22-012194.md","text":"https://secwatch.observer/filing/0000950170-22-012194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022012194/0000950170-22-012194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022012194/kzr-20220627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:56:42.036835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}